Beranda › Rabdomiosarkoma › Pennsylvania › Philadelphia
Uji klinis Rabdomiosarkoma di Philadelphia, PA
4 studi untuk Rabdomiosarkoma mencari peserta di lokasi sekitar Philadelphia (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Menerima pesertaFase 1
- The Children's Hospital of Philadelphia (CHOP), Philadelphia
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Menerima pesertaFase 3
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25 mi jauhnya
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Menerima pesertaFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Menerima pesertaFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
Uji klinis Rabdomiosarkoma di kota lain
- Houston, TX6 studi
- Memphis, TN6 studi
- Washington, DC5 studi
- Salt Lake City, UT4 studi
- Boston, MA4 studi
- Seattle, WA3 studi
- Birmingham, AL3 studi
- Dallas, TX3 studi
- Baltimore, MD3 studi
- The Bronx, NY3 studi
- Aurora, CO3 studi
Studi lain di Philadelphia
- Kanker (semua jenis)59 studi
- Kanker Payudara56 studi
- Kanker Paru Non-Sel Kecil51 studi
- Kanker Metastatik46 studi
- Kanker Prostat44 studi
- Kanker Kolorektal44 studi
- Kanker Ovarium44 studi
- Kanker Paru36 studi
- Leukemia Mieloid Akut34 studi
- Gagal Jantung31 studi
- Kanker Endometrium28 studi
- Depresi26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.